Medtronic Plc (MDT)

Medtronic's stock experienced several events over the past six months. The company released Q2 2026 earnings with an EPS of $1.070 USD and Q3 fiscal 2026 results with a non-GAAP EPS of $1.36, beating estimates but the stock lost approximately 5% in premarket trading. Medtronic disclosed a quarterly dividend of $0.71 per share. Analysts adjusted price targets for MDT, with some lowering and others raising their targets. Medtronic announced its intent to acquire Scientia Vascular for $550 million. The company received FDA clearance for its Stealth AXiS™ Surgical System and OmniaSecure™ defibrillation lead. As of April 10, 2026, the closing price was $87.21, down 0.80% from the previous day.

Information explicitly detailing the demand seasonality for Medtronic Plc's products and services is not readily available. However, the nature of Medtronic's products suggests that demand might be relatively stable rather than highly seasonal, as healthcare needs for chronic conditions and surgical interventions generally persist throughout the year. The company's diversified portfolio across various therapeutic areas also helps to mitigate potential seasonality in any single product line.

Medtronic Plc is a global leader in healthcare technology, specializing in device-based medical therapies and services. The company operates within the medical equipment industry, aiming to alleviate pain, restore health, and extend life through innovative solutions. Its portfolio is divided into four segments: Cardiovascular, focusing on heart-related conditions; Neuroscience, addressing neurological and spinal conditions; Medical Surgical, providing minimally invasive surgical solutions; and Diabetes, offering insulin pumps and continuous glucose monitoring systems. Medtronic has developed technologies such as wearable and implantable pacemakers, the implantable cardioverter-defibrillator (ICD), and miniaturized devices.

Medtronic has a significant global presence, operating in over 150 countries with over 95,000 employees across 350 locations. Its legal and executive headquarters are in Galway, Ireland, while operational headquarters are in Minneapolis, Minnesota, U.S. The company's network supports various functions, including R&D, manufacturing, sales, clinical research, education, distribution, and administration. Foreign sales account for approximately 50% of its total sales, and it reports operations in Ireland, the United States, and the Rest of the World.

Medtronic maintains a strong brand reputation as a global leader in healthcare technology, known for its innovation and diversified product portfolio. The company has received several IR Magazine Awards for its investor relations, indicating a positive perception among the investment community. While no significant negative events impacted its overall brand reputation, a slight revenue shortfall in Q3 fiscal 2025 due to shifts in U.S. distributor purchasing patterns and the impact of tariffs caused some investor concerns.

Medtronic Plc is largely controlled by institutional shareholders, who collectively own a significant portion of the company. As of April 9, 2026, Medtronic had 2319 institutional owners and shareholders holding a total of 1,089,763,752 shares. Institutional investors held 87% of the company as of July 23, 2025. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual investors hold a smaller stake, around 13% as of July 23, 2025, and insiders own less than 1% of Medtronic plc.